Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.33 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PLG | P00747 | 3/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5259088 | 0.92 | ITGB1 (0.41) | DRD1ITGB1ITGA4FFAR1PPARG | |
| SCHEMBL5260326 | 0.83 | ITGB1 (0.38) | ITGB1ITGA4PPARG | |
| SCHEMBL5262264 | 0.83 | ITGB1 (0.38) | ITGB1ITGA4PPARG | |
| SCHEMBL5260488 | 0.83 | ITGB1 (0.38) | DRD1ITGB1ITGA4FFAR1PPARG | |
| SCHEMBL5335132 | 0.83 | ELANE (0.34) | ELANESLC8A1KDM4C | |
| SCHEMBL5262517 | 0.82 | NLRP3 (0.33) | PPARG | |
| SCHEMBL5147510 | 0.80 | ITGB1 (0.44) | DRD1ELANEITGB1ITGA4SLC8A1 | |
| SCHEMBL7259520 | 0.79 | ITGB1 (0.41) | DRD1ELANEITGB1ITGA4FFAR1 | |
| SCHEMBL7259514 | 0.79 | ITGB1 (0.41) | DRD1ELANEITGB1ITGA4FFAR1 | |
| SCHEMBL5261695 | 0.79 | FFAR1 (0.36) | DRD1FFAR1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332132-B1 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | UCB PHARMA SA (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-20030229116-A1 | ENAMINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229116-A1 | ENAMINE DERIVATIVES | ITGB2, CCR1, CCR10 | DRD1 816/4885ELANE 229/4885ITGB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.